Business
OSE Immunotherapeutics Reports First Half 2025 Financial Results
OSE Immunotherapeutics Reports First Half 2025 Financial Results NANTES, France, October 15, 2025 – 7:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today reported its consolidated financial results for the first half of 2025. The half-year financial statements for 2025 were subject to a limited review by the Company’s statutory auditors and were approved by the Board of Directors on October 15, 2025. 2025 Half-Year Financial Results (IFRS) In million eurosH1 2024H1 2025R
About this update from Ose Immunotherapeutics Sa
[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"OSE Immunotherapeutics Reports First Half 2025 Financial Results","length":64,"tagName":"p"},{"type":"text","content":"NANTES, France, October 15, 2025 – 7:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today reported its consolidated financial results for the first half of 2025.","length":185,"tagName":"p"},{"type":"text","content":"The half-year financial statements for 2025 were subject to a limited review by the Company’s statutory auditors and were approved by the Board of Directors on October 15, 2025.","length":177,"tagName":"p"},{"type":"text","content":"2025 Half-Year Financial Results (IFRS)","length":39,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:33%;border-bottom:solid black 1pt;vertical-align:middle;","val":[{"type":"text","content":"In million euros","length":16,"tagName":"p","attribs":{}}]},{"style":"width:8.5%;vertical-align:middle;text-align:left;padding-left:10.0px;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"H1 2024","length":7,"tagName":"p","attribs":{}}]},{"style":"width:8.5%;vertical-align:middle;text-align:left;padding-left:10.0px;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"H1 2025","length":7,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:33%;vertical-align:middle;text-align:left;padding-left:25.0px;border-top:solid black 1pt;border-bottom:solid black 1pt;vertical-align:middle;","val":[{"type":"text","content":"Revenues","length":8,"tagName":"p","attribs":{}}]},{"style":"width:8.5%;vertical-align:middle;text-align:left;padding-left:10.0px;vertical-align:middle;","val":[{"type":"text","content":"69.0","length":4,"tagName":"p","attribs":{}}]},{"style":"width:8.5%;vertical-align:middle;text-align:left;padding-l...